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ABSTRACT.

THE

CARDINAL FEATURE OF Alzheimer disease is the ex-

tracellular deposition of proteinaceous amyloid-β fibrils as senile plaques.
Amyloid-β plays an essential role in disease diagnosis and is also thought by
many to be a key mediator of disease pathogenesis. As such, there are tremendous efforts underway to understand mechanisms of amyloid deposition. In
this context, it is notable that the actual term amyloid, represents a historical
misnomer (being derived from amylose, i.e., starch) and since this realization,
the contribution of carbohydrates in disease pathogenesis has largely been ignored. However, recently, two emerging lines of evidence indicate not only
that the interaction of carbohydrates with amyloid is a key event in disease
pathogenesis but also that therapeutic efforts targeted towards such pathways
may prove therapeutically efficacious. First, just over a decade ago, we and
others discovered that oxidative glycation, similar if not identical to that found
in diabetes, was an early and chronic contributor to the disease. Second, we
very recently found evidence for the presence of chitin-like polysaccharides in
association with amyloid deposits in the diseased brain. Both carbohydrateassociated changes likely contribute to the physiochemical properties of amyloid (and other disease-related proteins such as tau) and, as such, to the insolubility and protease-resistance of amyloid. In fact, taken together, the findings
indicate an emerging and important role for carbohydrates in the pathogenesis
of Alzheimer disease.
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ALZHEIMER DISEASE

Initially described in 1907 by Alois Alzheimer, this condition, which now bears his name,
describes a fatal neurodegenerative disorder that
starts with mild memory impairment and poor
judgment but progresses to apraxia, aphasia, and
agnosia. The latter stages are often characterized by
complete debilitation, requiring constant intensive
supervision. Following initial diagnosis, the course
of the disease varies from a few years to over 20
years, with an average of 4 to 8 years. Alzheimer's
disease (AD) is by far the most common cause of
senile dementia.
Originally, AD was viewed as two distinct
clinical conditions, depending on the age of onset.
Alzheimer’s disease was a term reserved for presenile (<65 years) dementia and senile dementia of
the Alzheimer-type was used to describe the condition in elderly (>65 years) patients. Although these
classifications are still used in reference to age of
onset, AD fails to demonstrate either a bimodal age
of onset or phenotypic differences and is therefore
recognized as a single entity with a prevalence that
increases sharply with age. Rare cases of AD have
been reported from the second and third decades of
life; however, the vast majority of patients are over
the age of 60 such that, within the United States,
10% of the population older than 65 years and as
many as 47% of those older than 85 years are afflicted.
The distinctive brain lesions, senile plaques
and neurofibrillary tangles, used by Alois Alzheimer together with the clinical deficits to describe the disease, are still used today as the defining features for diagnosis. In addition to these striking changes, there is variable cerebral cortical atrophy, particularly of the temporal and frontal lobes,
and associated ventricular dilation, both of which
are consequences of the neuron loss and astrocyte
proliferation in affected regions.
Both neurofibrillary tangles and senile plaques
are found in normal aged persons, but it is their
quantitative increase that defines the pathologic
diagnosis of AD. Neurofibrillary tangles consist of
abnormal 20-nm helical filaments with an 80-nm

half-periodicity, termed paired helical filaments,
and 12- to 15-nm straight filaments. Paired helical
and straight filaments occur not only in neuronal
perikaryon as neurofibrillary tangles, but also
within dendrites and axons as neuropil threads, and
within synaptic terminals of the large dystrophic
neurites surrounding the amyloid-β deposits of senile plaques. The amyloid-β of senile plaques consists of 7- to 10-nm helical filaments that share
with paired helical filaments the ability to bind the
dye Congo red and appear birefringent green when
viewed under cross-polarized light, a property of βpleated molecular sheets. Amyloid-β deposits in
senile plaques are found almost exclusively in cortical and subcortical gray matter, where they can
take the form of either closely opposed filaments
termed cores or loose deposits termed diffuse.
Amyloid-β is also found in meningeal and graymatter blood vessels, termed congophilic angiopathy, although the pathobiologic significance of vascular amyloid-β is unclear.

CARBOHYDRATES AND ALZHEIMER DISEASE
Studies related to the role of carbohydrates in
the pathophysiology of amyloidosis date back to
Virchow [1] and the introduction of the term “corpora amylacea” (amyloid bodies) for microscopic
lesions within the brain and spinal cord that demonstrated an affinity for iodine. Only a few years
later Friedreich and Kekule [2] used a similar term
“amyloid” to describe extracellular accumulations
in peripheral organs. It is now apparent that Virchow was describing CNS corpora amylacea, being
intraastrocytic accumulations of carbohydrate material and was correct in his interpretation that the
material reacted chemically like starch. On the
other hand, the “amyloid” as assessed by Friedreich
and Kekule corresponds to amyloid as it is known
currently, being a collection of extracellular, insoluble fibrils considered largely proteinaceous in
composition, with positive staining for thioflavin,
and “apple green” birefringence on plane polarized
light following Congo red staining [3]. Noteworthy
examples of proteins capable for forming amyloid
include amyloid-β, prion protein, transthyretin, se-
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rum amyloid A, immunoglobulin light chain, and
gelsolin.
Friedreich and Kekule appropriately disagreed
with the histochemical findings that Virchow described, but they were incorrect in assuming that it
was the same material. Nevertheless, the term
“amyloid,” the root of which indicates amylose
(i.e., starch), was retained and is now used to described amorphous accumulations of protein fibrils
with a high β-sheet content.

PROTEOGLYCANS IN ALZHEIMER DISEASE
Little additional progress into the carbohydrate-protein interaction in amyloidosis was made
until the late 1960’s when acid mucopolysaccharides (glycosaminoglycans) were demonstrated in
association amyloid fibrils [4, 5]. Liver and spleen
amyloid in inflammation-associated and light
chain-associated amyloidosis were associated with
highly sulfated glycosaminoglycans (GAGs) (e.g.,
heparan sulphate) [4, 6, 7], while senile cardiac
amyloidosis was associated with hyaluronic acid
[8, 9]. Since these studies only assessed the glycosaminoglycan composition in amyloid deposits in
end stage disease, it was unclear whether GAG
deposition was concurrent with amyloid deposits or
was a secondary phenomenon. Other investigators
later demonstrated that deposits of highly sulfated
GAGs and amyloid protein was concurrent in experimentally induced amyloidosis [10] and suggested that highly sulfated GAGs were specifically
related to the pathogenesis in a variety of amyloidoses including Alzheimer’s disease [11]. Ultrastructural studies further suggested a close association between AA amyloid fibrils and heparan sulfate proteoglycans [12].
Not surprisingly, histochemical studies have
shown that heparan sulfate colocalizes with amyloid-β, consistent with lectin binding studies demonstrating individual components of GAGs units
such as N-acetyl-D-glucosamine [13], and immunohistochemical localization of heparan sulfate
proteoglycan core protein to neuritic plaques and
cerebrovascular amyloid deposits in brains of AD
[14,15]. Additional investigations determined the

presence of chondroitin sulfate [16], decorin, a
dermatan sulfate proteoglycan [17] and keratan
sulfate proteoglycans [18]. Interestingly, unlike
HSPGs which are colocalized with amyloid firbrils
throughout the senile plaques, chondroitin sulfate
and dermamatan sulfate proteoglycans are confined
to the periphery, thereby surrounding the plaque
cores. This suggests that the different classes of
GAGs may be playing different roles during the
course of the disease.
Proteoglycans are not only associated with the
amyloid deposits of the senile plaques as they are
also found in the neurofibrillary tangles in Alzheimer’s disease [19]. Moreover, both HSPGs and
chondroitin sulfate are present in the neuronal inclusions of a variety of neurodegenerative diseases
[20,21].
While the precise role of proteoglycans is not
known, some experimental evidence suggests that
they promote amyloid deposition [22], and that
amyloid-β hampers heparanase-catalyzed degradation in vitro, promoting amyloid-β deposition and
accumulation [23]. Other studies have suggested
that sulfate moieties of GAGs may be important to
amyloid-β fibrillogenesis [24] and can inhibit proteolysis of amyloid-β fibrils [25]. Sulfated GAGs
are also involved in the formation of Alzheimerlike PHFs from recombinant tau protein [26] and
also promote the insolubility of PHFs [27]. Importantly, at least one form of the amyloid precursor
protein is itself a chondroitin sulfate proteoglycan
[28].

METABOLIC COMPROMISE IN ALZHEIMER
DISEASE
In light of increasing evidence of altered glucose metabolism in AD [29-31], we were interested
in exploring whether excessive glucosamine as a
result of hexosamine pathway activation [as occurs,
for example, in diabetes mellitus [32] led to the
synthesis of glucosamine polymers. Glucosamine,
the basic unit of chitin and chito-saccharides, is
formed from glucose via fructose and fructose-6phosphate. High levels of glucose, and glucosamine
via subsequent hexosamine pathway activation, due
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to impaired glucose metabolism in AD at the cellular level, in the presence of the normal complement
of cellular enzymes, might lead to the production of
glucose polymers (starch) and glucosamine polymers (chitin) respectively. In a recent study, we
verified the presence of glucose polymers (amylose) in the AD brain [33]. Subsequently, we turned
to the issue of glucosamine and glucosamine polymers in AD by examining brain tissue from subjects with sporadic and familial early onset AD
(presenilin A431E mutation) for calcofluor reactivity [34]. Calcofluor, a fluorochrome that excites on
exposure to ultraviolet light, exhibits a high affinity
for chitin in vivo by interacting with β1-4 linkages
[35], and is a practical technique for demonstrating
chitin in tissues, as chitin is a linear polymer of
glucosamine in β1-4 linkage. Interestingly, it has
been demonstrated in yeast that chitin cell wall assembly is altered not only by calcofluor but also
Congo red [36].

CHITIN-LIKE POLYSACCHARIDES IN ALZHEIMER
DISEASE
In both sporadic and familial early onset AD,
plaques of all types of all types – diffuse, neuritic,
cored, cotton-wool – and blood vessels affected by
amyloid angiopathy, strongly labeled using calcofluor histochemistry [35,37]. The parallel between the distribution of labeling with calcofluor
histochemistry and amyloid-β immunohistochemistry was striking, with the only exception that calcofluor also stained a subset of neurofibrillary tangles in addition to plaques and blood vessels with
amyloid angiopathy. To confirm specificity of the
calcofluor reaction for β1-4 linked glucosamine,
AD tissues were subjected to chitinase (which degrades chitin to chitobiose), followed N-acetyl glucosaminidase, and found a significant decrease in
calcofluor staining, indicating that degradation into
individual monosaccharide units is necessary to
diminish the calcofluor reaction, and confirming
specificity of calcofluor in AD for chitin-like polysaccharides. This fundamental finding of colocalization of calcofluor histochemical reactivity
and amyloid-β immunohistochemistry suggests that

chitin or chitin-like polysaccharides comprise an
integral component of amyloid deposits.
Since chitin is highly insoluble, our studies
raise the question of whether protein is purely responsible for the chemical properties of amyloid, or
whether chitin-like polysaccharides influence these
features as well. It is noteworthy that commercial
chitin stains red with Congo Red and also shows
green birefringence with plane polarized light (data
not shown). This, in addition to calcoflour staining
of amyloid plaques and amyloid angiopathy, is
consistent with the concept that chitin influences
the histochemical properties of amyloid previously
ascribed to protein secondary structure. It should
also be noted that diffuse plaques, and cotton wool
plaques of familial early onset AD, lack the characteristic filamentous amyloid by electron microscopy [38]. Likewise, calcofluor staining was more
widespread than Congo red staining in the AD
brain. Thus, chitin-like polysaccharides overall are
more widespread than protein fibrils of classically
defined amyloid, suggesting that accumulation of
N-acetyl glucosamine precedes formation of typical
amyloid fibrils.
Whether brain chitin accumulation provides a
protective or a deleterious function remains an important unanswered question. Commercial chitin
and one of its derivatives, chitosan, have applications in wound healing and enhancement of function of inflammatory cells and fibroblasts [39];
thus, chitin within the brain may stimulate inflammatory processes such as microglial cell activation
and elaboration of soluble mediators of immunity,
processes which are becoming increasingly apparent in AD pathogenesis [40]. Moreover, our group
and others have demonstrated that amyloid plaques
are an indication of neuroprotection (e.g., by transition metal binding and diminishing cytotoxicity
associated with free radicals), rather than an indication of tissue injury [41-43]. Chitin, therefore, may
have a reparative or protective function in the human brain by sequestering amyloid-β and associated neurotoxic metabolites.
Our studies have provided empirical evidence
of the presence of chitin or chitin-like material in
the AD brain, largely in association with amyloid-β
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deposits. However, it is important to recognize the
complexity of the process of chitin synthesis and
the unanswered questions that remain. Chitin synthesis is an energy-dependent process, requiring an
N-Acetylglucosaminyltransferase using the uridine
diphosphate (UDP)-activated monomer as the sugar
donor [44], or a chitin synthase. While no definitive
mammalian chitin synthase has been identified, a
potential developmental role of chitooligosaccharides in vertebrate animals has been suggested in
several studies [45-47]. Hyaluronan synthase-1
(HAS1) has been shown to convert activated glucosamine to chito-oligosaccharides in vitro using
murine HAS1 gene product [48]. In addition, human synovial fluid of patients with rheumatoid or
osteoarthritis contains high levels of a chitinase 3like glycoprotein [49]. Thus, under pathological
conditions, HAS1 may serve as a chitin synthase,
converting activated glucosamine to chitin-like
polysaccharides and facilitating the process of amyloidosis.
While chitin is extracellular, its precursor,
UDP-N-acetylglucosamine is intracellular. The precise mechanism whereby chitin is transport through
the cell membrane and deposited in the extracellular space therefore remains to be elucidated. In this
respect, however, it is interest to note the focal
presence of calcofluor reactivity within neurons
affected by neurofibrillary tangle formation.

GLYCATION IN ALZHEIMER DISEASE
Advanced glycation endproducts (AGEs)
comprise a diverse class of irreversible posttranslational modifications, with a propensity to form
crosslinks, render proteins insoluble, interact with
cell surface receptors to produce deleterious biochemical effects, and generate reactive oxygen species. While AGEs have long been associated with
diabetes mellitus and senile cataracts, where high
concentrations of glucose and other sugar metabolites predisposes to AGE formation, more recently,
we and others demonstrated a number of AGE species in neurodegenerative diseases, including Alzheimer disease (AD) [50-53] and Parkinson disease
[54]. In AD, AGEs were found in parallel with

pathologic lesions [55] as well as in morphologically normal neurons (Smith and Perry, unpublished), suggesting that AGEs are not only a critical
factor leading to the formation of hallmark inclusions [50,55], but are also part of the early changes
seen in the disease process.
The initial step in AGE formation is the nonenzymatic attachment of sugar aldehydes or ketones to the side chains of lysine, arginine, and possibly histidine. The lysine ε-amino-derived glycation product, or Schiff base, rearranges to form a
more stable amino ketone intermediate known as
the Amadori product. The Amadori product can
then evolve to a number of structurally more complex covalently-linked AGEs by irreversible dehydration and additional crosslinking. It is not perhaps surprising that lysine-rich proteins, such as τ,
neurofilament protein, and αB crystalline, target
proteins rendered insoluble by AGE modification,
accumulate as insoluble inclusions that represent
histopathological hallmarks of disease [50,55]. The
presence of the Amadori product, indicative of active glycation, can be demonstrated by its reduction
to a stable epimeric mixture of 1-glycitol-lysine
and 1-mannitol-lysine, known collectively as hexitol-lysine.
Immunocytochemical and biochemical studies
have suggested that one particular AGE, Nε(Carboxymethyl)lysine (CML) is the major AGE
that accumulates in vivo [56-59]. Elevated serum
levels of CML are detected in patients with diabetes mellitus [59] and CML is increased in the vascular tissues of diabetic rodents and humans [6063]. Moreover, co-localization of CML with adducts derived from products of lipid peroxidation,
products of 4-hydroxy-2-nonenal and malondialdehyde, supports the concept that lipid peroxidation
itself, in addition to and apart from advanced glycation, triggers the formation of CML [64].
The purpose of this study was to elucidate the
role of CML and hexitol-lysine in the pathogenesis
of AD. Our findings of concurrent increases in both
end stage modification as well as the initial
Amadori products of sugar adduction, provide evidence for an active glycation process in AD.
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SUMMARY

The role of carbohydrates in the pathogenesis
of various amyloidoses, including AD, is only beginning to be understood. While sulfated proteoglycans may play a role in fibrillogenesis, the
identification of novel chitin-like polysaccharides
in the AD brain, polysaccharides that are particularly suited to protein nucleation, may in large
measure explain the biochemical characteristics of
amyloid in general. While further studies are necessary to determine whether chitin is protective or
deleterious, the data presented here provide evidence that chitin, previously unrecognized in humans, may be intimately associated with AD, amyloidosis, and the aging process. The implications of
these data in terms of treatment advances and understanding of disease pathogenesis are considerable.
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